Transplantační medicína

Nejnovější trendy

Prozkoumejte nejčtenější články a videa na Campus Sanofi

Seřadit

EAS 2025: Προφίλ καρδιαγγειακών ασθενών σε όλο το φάσμα της ASCVD

Číst více

Patient morbidity and mortality in BP

Many factors, including older age and multimorbidity, are associated with mortality in bullous pemphigoid. Read this article to find out more

Číst více

What is Bullous Pemphigoid

The heterogeneous presentation of bullous pemphigoid may shed light on why patients are underdiagnosed. Read the article to learn more

Číst více

Patient morbidity and mortality in BP

Many factors, including older age and multimorbidity, are associated with mortality in bullous pemphigoid. Read this article to find out more

Číst více

What is Bullous Pemphigoid

The heterogeneous presentation of bullous pemphigoid may shed light on why patients are underdiagnosed. Read the article to learn more

Číst více

Patient morbidity and mortality in BP

Many factors, including older age and multimorbidity, are associated with mortality in bullous pemphigoid. Read this article to find out more

Číst více

What is Bullous Pemphigoid

The heterogeneous presentation of bullous pemphigoid may shed light on why patients are underdiagnosed. Read the article to learn more

Číst více

Patient morbidity and mortality in BP

Many factors, including older age and multimorbidity, are associated with mortality in bullous pemphigoid. Read this article to find out more

Číst více

What is Bullous Pemphigoid

The heterogeneous presentation of bullous pemphigoid may shed light on why patients are underdiagnosed. Read the article to learn more

Číst více

Treatments and challenges for bullous pemphigoid

Systemic corticosteroids and other immunosuppressants are the current mainstay of therapy but carry risks for patients with bullous pemphigoid. Read this article to find out more

Číst více

Treatments and challenges for bullous pemphigoid

Systemic corticosteroids and other immunosuppressants are the current mainstay of therapy but carry risks for patients with bullous pemphigoid. Read this article to find out more

Číst více

Pathophysiology of Bullous Pemphigoid

In bullous pemphigoid, autoimmunity to BP180 and BP230 is thought to trigger a type 2 inflammatory response. Read this article to find out more

Číst více